1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Top 50 Big Biotech Partnering and M&A Deal Trends 2010-2015 - CP1011 - Apr2015

The Top 50 Big Biotech Partnering and M&A Deal Trends report provides comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big biotech companies
Over 300 charts showing a company’s dealmaking activity since 2009, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2010 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

This premier report provides all the information you require to better understand big biotech partnering.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of each big biotech companies dealmaking trends over the last four years.

This report contains over 1,500 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by big biotech and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of big biotech’s dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2013 pharmaceutical revenues and dealmaking activity since 2009.

Chapter 3 reviews the top partnering and M&A deals of 2010-2015 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to big biotech, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big biotech provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of every big biotech company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partner’s negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This data driven report contains over 1,500 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
In summary, the report provides the reader with the tools necessary to make successful contact with the right big biotech partners effectively and efficiently.

Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big biotech companies
Over 300 charts showing a company’s dealmaking activity since 2010, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2010 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 1,500 partnering deals, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Top 50 Big Biotech Partnering and MandA Deal Trends 2010-2015 - CP1011 - Apr2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Big biotech top 50 dealmaking activity

2.1. Introduction
2.2. Big biotech partnering over the years
2.3. Big biotech partnering by deal type
2.4. Big biotech partnering by stage of development
2.5. Big biotech partnering by technology type
2.6. Big biotech partnering by therapy area
2.7. Big biotech MandA over the years

Chapter 3 - Top big biotech deals by value

3.1. Introduction
3.2. Big biotech partnering
3.3. Big biotech MandA

Chapter 4 - Submitting Opportunities to Big biotech

4.1. How to submit an opportunity
4.2. Opportunity submission template
4.3. Sending emails
4.4. Face to face at partnering events
4.5. Online submission forms

Chapter 5 - Forthcoming big biotech partnering events

5.1. Forthcoming events

Chapter 6 - Big Biotech Company Profiles

6.1. Introduction
6.2. Field definitions
6.3. Company profiles
Acorda Therapeutics
Actavis
Actelion
Alexion Pharmaceuticals
Alkermes
Allergan
Amgen
Bavarian Nordic
Biocon
Biogen Idec
BioMarin Pharmaceuticals
Celgene
CSL
Cubist
Dendreon
Emergent BioSolutions
Endo
Galapagos
Genmab
Gilead Sciences
Grifols
Ipsen
Isis Pharmaceuticals
Jaxx Pharmaceuticals
LFB Group
Medivation
Merck KGaA
Morphosys
Nektar Therapuetics
Novo Nordisk
NPS Pharmaceuticals
PDL BioPharma
Pharmacyclics
Questcor Pharmaceuticals
Regeneron Pharmaceuticals
Roche
Salix Pharmaceuticals
SciClone Pharmaceuticals
Seattle Genetics
Shire
Spectrum Pharmaceuticals
Sun Pharmaceutical
Swedish Orphan Biovitrum
Teva
The Medicines Company
UCB
United Therapeutics
Valeant
Vertex Pharmaceuticals

Chapter 7 - Resources

Appendices
Appendix 1 - Deal type definitions
Appendix 2 - Example contract document
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form - Upgrades to subscription access products

TABLE OF FIGURES

Figure 1: Big biotech partnering 2010-2015
Figure 2: Big biotech - top 50 partnering activity 2010 to 2015
Figure 3: Big biotech deal frequency - 2010 to 2015
Figure 4: Big biotech partnering by deal type 2010-2015
Figure 5: Big biotech partnering by stage of development 2010-2015
Figure 6: Big biotech partnering by technology type 2010-2015
Figure 7: Big biotech partnering by therapy area 2010-2015
Figure 8: Big biotech MandA 2010-2015
Figure 9: Big biotech - top 50 MandA activity 2010-2015
Figure 10: Big biotech MandA deal frequency 2010-2015
Figure 11: Leading partnering deals by value, 2010-2015
Figure 12: Leading MandA deals involving big biotech by value, 2010-2015
Figure 13: Typical partnering opportunity submission template
Figure 14: Company profile template and definitions used in report
Figure 15: Acorda Therapeutics dealmaking frequency 2010-2015
Figure 16: Acorda Therapeutics deals by type
Figure 17: Acorda Therapeutics deals by industry sector
Figure 18: Acorda Therapeutics deals by technology type
Figure 19: Acorda Therapeutics deals by stage of development
Figure 20: Partnering deals by therapy area
Figure 21: Actavis dealmaking frequency 2010-2015
Figure 22: Actavis deals by type
Figure 23: Actavis deals by industry sector
Figure 24: Actavis deals by technology type
Figure 25: Actavis deals by stage of development
Figure 26: Actavis deals by therapy area
Figure 27: Actelion dealmaking frequency 2010-2015
Figure 28: Actelion deals by type
Figure 29: Actelion deals by industry sector
Figure 30: Actelion deals by technology type
Figure 31: Actelion deals by stage of development
Figure 32: Actelion deals by therapy area
Figure 33: Alexion Pharmaceuticals dealmaking frequency 2010-2015
Figure 34: Alexion Pharmaceuticals deals by type
Figure 35: Alexion Pharmaceuticals deals by industry sector
Figure 36: Alexion Pharmaceuticals deals by technology type
Figure 37: Alexion Pharmaceuticals deals by stage of development
Figure 38: Alexion Pharmaceuticals deals by therapy area
Figure 39: Alkermes dealmaking frequency 2010-2015
Figure 40: Alkermes deals by type
Figure 41: Alkermes deals by industry sector
Figure 42: Alkermes deals by technology type
Figure 43: Alkermes deals by stage of development
Figure 44: Alkermes deals by therapy area
Figure 45: Allergan dealmaking frequency 2010-2015
Figure 46: Allergan deals by type
Figure 47: Allergan deals by industry sector
Figure 48: Allergan deals by technology type
Figure 49: Allergan deals by stage of development
Figure 50: Allergan deals by therapy area
Figure 51: Amgen dealmaking frequency 2010-2015
Figure 52: Amgen deals by type
Figure 53: Amgen deals by industry sector
Figure 54: Amgen deals by technology type
Figure 55: Amgen deals by stage of development
Figure 56: Amgen deals by therapy area
Figure 57: Bavarian Nordic dealmaking frequency 2010-2015
Figure 58: Bavarian Nordic deals by type
Figure 59: Bavarian Nordic deals by industry sector
Figure 60: Bavarian Nordic deals by technology type
Figure 61: Bavarian Nordic deals by stage of development
Figure 62: Bavarian Nordic deals by therapy area
Figure 63: Biocon dealmaking frequency 2010-2015
Figure 64: Biocon deals by type
Figure 65: Biocon deals by industry sector
Figure 66: Biocon deals by technology type
Figure 67: Biocon deals by stage of development
Figure 68: Biocon deals by therapy area
Figure 69: Biogen Idec dealmaking frequency 2010-2015
Figure 70: Biogen Idec deals by type
Figure 71: Biogen Idec deals by industry sector
Figure 72: Biogen Idec deals by technology type
Figure 73: Biogen Idec deals by stage of development
Figure 74: Biogen Idec deals by therapy area
Figure 75: BioMarin Pharmaceuticals dealmaking frequency 2010-2015
Figure 76: BioMarin Pharmaceuticals deals by type
Figure 77: BioMarin Pharmaceuticals deals by industry sector
Figure 78: BioMarin Pharmaceuticals deals by technology type
Figure 79: BioMarin Pharmaceuticals deals by stage of development
Figure 80: BioMarin Pharmaceuticals deals by therapy area
Figure 81: Celgene dealmaking frequency 2010-2015
Figure 82: Celgene deals by type
Figure 83: Celgene deals by industry sector
Figure 84: Celgene deals by technology type
Figure 85: Celgene deals by stage of development
Figure 86: Celgene deals by therapy area
Figure 87: CSL dealmaking frequency 2010-2015
Figure 88: CSL deals by type
Figure 89: CSL deals by industry sector
Figure 90: CSL deals by technology type
Figure 91: CSL deals by stage of development
Figure 92: CSL deals by therapy area
Figure 93: Cubist dealmaking frequency 2010-2015
Figure 94: Cubist partnering deals by type
Figure 95: Cubist deals by industry sector
Figure 96: Cubist deals by technology type
Figure 97: Cubist deals by stage of development
Figure 98: Cubist deals by therapy area
Figure 99: Dendreon dealmaking frequency 2010-2015
Figure 100: Dendreon deals by type
Figure 101: Dendreon deals by industry sector
Figure 102: Dendreon deals by technology type
Figure 103: Dendreon deals by stage of development
Figure 104: Dendreon deals by therapy area
Figure 105: Emergent BioSolutions dealmaking frequency 2010-2015
Figure 106: Emergent BioSolutions deals by type
Figure 107: Emergent BioSolutions deals by industry sector
Figure 108: Emergent BioSolutions deals by technology type
Figure 109: Emergent BioSolutions deals by stage of development
Figure 110: Emergent BioSolutions deals by therapy area
Figure 111: Endo dealmaking frequency 2010-2015
Figure 112: Endo deals by type
Figure 113: Endo deals by industry sector
Figure 114: Endo deals by technology type
Figure 115: Endo deals by stage of development
Figure 116: Endo deals by therapy area
Figure 117: Galapagos dealmaking frequency 2010-2015
Figure 118: Galapagos deals by type
Figure 119: Galapagos deals by industry sector
Figure 120: Galapagos deals by technology type
Figure 121: Galapagos deals by stage of development
Figure 122: Galapagos deals by therapy area
Figure 123: Genmab dealmaking frequency 2010-2015
Figure 124: Genmab deals by type
Figure 125: Genmab deals by industry sector
Figure 126: Genmab deals by technology type
Figure 127: Genmab deals by stage of development
Figure 128: Genmab deals by therapy area
Figure 129: Gilead Sciences dealmaking frequency 2010-2015
Figure 130: Gilead Sciences deals by type
Figure 131: Gilead Sciences deals by industry sector
Figure 132: Gilead Sciences deals by technology type
Figure 133: Gilead Sciences deals by stage of development
Figure 134: Gilead Sciences deals by therapy area
Figure 135: Grifols dealmaking frequency 2010-2015
Figure 136: Grifols deals by type
Figure 137: Grifols deals by industry sector
Figure 138: Grifols deals by technology type
Figure 139: Grifols deals by stage of development
Figure 140: Grifols deals by therapy area
Figure 141: Ipsen dealmaking frequency 2010-2015
Figure 142: Ipsen deals by type
Figure 143: Ipsen deals by industry sector
Figure 144: Ipsen deals by technology type
Figure 145: Ipsen deals by stage of development
Figure 146: Ipsen deals by therapy area
Figure 147: Isis Pharmaceuticals dealmaking frequency 2010-2015
Figure 148: Isis Pharmaceuticals deals by type
Figure 149: Isis Pharmaceuticals deals by industry sector
Figure 150: Isis Pharmaceuticals deals by technology type
Figure 151: Isis Pharmaceuticals deals by stage of development
Figure 152: Isis Pharmaceuticals deals by therapy area
Figure 153: Jazz Pharmaceuticals dealmaking frequency 2010-2015
Figure 154: Jazz Pharmaceuticals deals by type
Figure 155: Jazz Pharmaceuticals deals by industry sector
Figure 156: Jazz Pharmaceuticals deals by technology type
Figure 157: Jazz Pharmaceuticals deals by stage of development
Figure 158: Jazz Pharmaceuticals deals by therapy area
Figure 159: LFB dealmaking frequency 2010-2015
Figure 160: LFB deals by type
Figure 161: LFB deals by industry sector
Figure 162: LFB deals by technology type
Figure 163: LFB deals by stage of development
Figure 164: LFB deals by therapy area
Figure 165: Medivation dealmaking frequency 2010-2015
Figure 166: Medivation deals by type
Figure 167: Medivation deals by industry sector
Figure 168: Medivation deals by technology type
Figure 169: Medivation deals by stage of development
Figure 170: Medivation deals by therapy area
Figure 171: Merck KGaA dealmaking frequency 2010-2015
Figure 172: Merck KGaA deals by type
Figure 173: Merck KGaA deals by industry sector
Figure 174: Merck KGaA deals by technology type
Figure 175: Merck KGaA deals by stage of development
Figure 176: Merck KGaA deals by therapy area
Figure 177: Morphosys dealmaking frequency 2010-2015
Figure 178: Morphosys deals by type
Figure 179: Morphosys deals by industry sector
Figure 180: Morphosys deals by technology type
Figure 181: Morphosys deals by stage of development
Figure 182: Morphosys deals by therapy area
Figure 183: Nektar Therapeutics dealmaking frequency 2010-2015
Figure 184: Nektar Therapeutics deals by type
Figure 185: Nektar Therapeutics deals by industry sector
Figure 186: Nektar Therapeutics deals by technology type
Figure 187: Nektar Therapeutics deals by stage of development
Figure 188: Nektar Therapeutics deals by therapy area
Figure 189: Novo Nordisk dealmaking frequency 2010-2015
Figure 190: Novo Nordisk deals by type
Figure 191: Novo Nordisk deals by industry sector
Figure 192: Novo Nordisk deals by technology type
Figure 193: Novo Nordisk deals by stage of development
Figure 194: Novo Nordisk deals by therapy area
Figure 195: NPS Pharmaceuticals dealmaking frequency 2010-2015
Figure 196: NPS Pharmaceuticals deals by type
Figure 197: NPS Pharmaceuticals deals by industry sector
Figure 198: NPS Pharmaceuticals deals by technology type
Figure 199: NPS Pharmaceuticals deals by stage of development
Figure 200: NPS Pharmaceuticals deals by therapy area
Figure 201: PDL BioPharma dealmaking frequency 2010-2015
Figure 202: PDL BioPharma deals by type
Figure 203: PDL BioPharma deals by industry sector
Figure 204: PDL BioPharma deals by technology type
Figure 205: PDL BioPharma deals by stage of development
Figure 206: PDL BioPharma deals by therapy area
Figure 207: Pharmacyclics dealmaking frequency 2010-2015
Figure 208: Pharmacyclics deals by type
Figure 209: Pharmacyclics deals by industry sector
Figure 210: Pharmacyclics deals by technology type
Figure 211: Pharmacyclics deals by stage of development
Figure 212: Pharmacyclics deals by therapy area
Figure 213: Questcor Pharmaceuticals dealmaking frequency 2010-2015
Figure 214: Questcor Pharmaceuticals deals by type
Figure 215: Questcor Pharmaceuticals deals by industry sector
Figure 216: Questcor Pharmaceuticals deals by technology type
Figure 217: Questcor Pharmaceuticals deals by stage of development
Figure 218: Questcor Pharmaceuticals deals by therapy area
Figure 219: Regeneron Pharmaceuticals dealmaking frequency 2010-2015
Figure 220: Regeneron Pharmaceuticals deals by type
Figure 221: Regeneron Pharmaceuticals deals by industry sector
Figure 222: Regeneron Pharmaceuticals deals by technology type
Figure 223: Regeneron Pharmaceuticals deals by stage of development
Figure 224: Regeneron Pharmaceuticals deals by therapy area
Figure 225: Roche dealmaking frequency 2010-2015
Figure 226: Roche deals by type
Figure 227: Roche deals by industry sector
Figure 228: Roche deals by technology type
Figure 229: Roche deals by stage of development
Figure 230: Roche deals by therapy area
Figure 231: Salix Pharmaceuticals dealmaking frequency 2010-2015
Figure 232: Salix Pharmaceuticals deals by type
Figure 233: Salix Pharmaceuticals deals by industry sector
Figure 234: Salix Pharmaceuticals deals by technology type
Figure 235: Salix Pharmaceuticals deals by stage of development
Figure 236: Salix Pharmaceuticals deals by therapy area
Figure 237: SciClone Pharmaceuticals dealmaking frequency 2010-2015
Figure 238: SciClone Pharmaceuticals deals by type
Figure 239: SciClone Pharmaceuticals deals by industry sector
Figure 240: SciClone Pharmaceuticals deals by technology type
Figure 241: SciClone Pharmaceuticals deals by stage of development
Figure 242: SciClone Pharmaceuticals deals by therapy area
Figure 243: Seattle Genetics dealmaking frequency 2010-2015
Figure 244: Seattle Genetics deals by type
Figure 245: Seattle Genetics deals by industry sector
Figure 246: Seattle Genetics deals by technology type
Figure 247: Seattle Genetics deals by stage of development
Figure 248: Seattle Genetics deals by therapy area
Figure 249: Shire dealmaking frequency 2010-2015
Figure 250: Shire deals by type
Figure 251: Shire deals by industry sector
Figure 252: Shire deals by technology type
Figure 253: Shire deals by stage of development
Figure 254: Shire deals by therapy area
Figure 255: Spectrum Pharmaceuticals dealmaking frequency 2010-2015
Figure 256: Spectrum Pharmaceuticals deals by type
Figure 257: Spectrum Pharmaceuticals deals by industry sector
Figure 258: Spectrum Pharmaceuticals deals by technology type
Figure 259: Spectrum Pharmaceuticals deals by stage of development
Figure 260: Spectrum Pharmaceuticals deals by therapy area
Figure 261: Sun Pharmaceutical dealmaking frequency 2010-2015
Figure 262: Sun Pharmaceutical deals by type
Figure 263: Sun Pharmaceutical deals by industry sector
Figure 264: Sun Pharmaceutical deals by technology type
Figure 265: Sun Pharmaceutical deals by stage of development
Figure 266: Sun Pharmaceutical deals by therapy area
Figure 267: Swedish Orphan Biovitrum dealmaking frequency 2010-2015
Figure 268: Swedish Orphan Biovitrum deals by type
Figure 269: Swedish Orphan Biovitrum deals by industry sector
Figure 270: Swedish Orphan Biovitrum deals by technology type
Figure 271: Swedish Orphan Biovitrum deals by stage of development
Figure 272: Swedish Orphan Biovitrum deals by therapy area
Figure 273: Teva dealmaking frequency 2010-2015
Figure 274: Teva deals by type
Figure 275: Teva deals by industry sector
Figure 276: Teva deals by technology type
Figure 277: Teva deals by stage of development
Figure 278: Teva deals by therapy area
Figure 279: The Medicines Company dealmaking frequency 2010-2015
Figure 280: The Medicines Company deals by type
Figure 281: The Medicines Company deals by industry sector
Figure 282: The Medicines Company deals by technology type
Figure 283: The Medicines Company deals by stage of development
Figure 284: The Medicines Company deals by therapy area
Figure 285: UCB dealmaking frequency 2010-2015
Figure 286: UCB deals by type
Figure 287: UCB deals by industry sector
Figure 288: UCB deals by technology type
Figure 289: UCB deals by stage of development
Figure 290: UCB deals by therapy area
Figure 291: United Therapeutics dealmaking frequency 2010-2015
Figure 292: United Therapeutics deals by type
Figure 293: United Therapeutics deals by industry sector
Figure 294: United Therapeutics deals by technology type
Figure 295: United Therapeutics deals by stage of development
Figure 296: United Therapeutics deals by therapy area
Figure 297: Valeant: Dealmaking frequency 2010-2015
Figure 298: Valeant: Partnering deals by type
Figure 299: Valeant: Partnering deals by industry sector
Figure 300: Valeant: Partnering deals by technology type
Figure 301: Valeant: Partnering deals by stage of development
Figure 302: Valeant: Partnering deals by therapy area
Figure 303: Vertex Pharmaceuticals dealmaking frequency 2010-2015
Figure 304: Vertex Pharmaceuticals deals by type
Figure 305: Vertex Pharmaceuticals deals by industry sector
Figure 306: Vertex Pharmaceuticals deals by technology type
Figure 307: Vertex Pharmaceuticals deals by stage of development
Figure 308: Vertex Pharmaceuticals deals by therapy area
Figure 309: Online partnering resources
Figure 310: Deal type definitions
Figure 311: Licensing and collaboration agreement between Bayer Healthcare and Regeneron Pharmaceuticals, January 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.